Diligence memo · auto-generated · as of July 2, 2026
Ralexar Therapeutics, Inc.
Ralexar Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Ralexar Therapeutics, Inc. operates in Pharmaceuticals, based in Encinitas.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ralexar Therapeutics, Inc. has raised $19M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $11M on 2014-01-03.
Most recent recorded round closed around 2018-12-20.
Valuation (modeled)modeled
Provath models Ralexar Therapeutics, Inc. at approximately $132M (range $4.9M–$720M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.74× the median modeled value of Series A Pharmaceuticals companies in 2016–2018 (88 peers) — value vs value, same stage and era. Within the normal band (74% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 7.5 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 65% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 60% of those peers.
Closest niche peers: Arbutus Biopharma Corp, Rvc 360, Llc, Sterrx, Llc, Ribometrix, Inc., Neuraltus Pharmaceuticals, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.